載入...
ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
Public Library of Science
2009
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2699476/ https://ncbi.nlm.nih.gov/pubmed/19568437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006124 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|